SCHEMBL14736715

SCHEMBL14736715

CCC(CC)C(=O)OC(C)(C)COc1c(-c2cccc3c2CCC3=O)ccc(OC)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
GAA P10253 1/20 0.36
HDAC4 P56524 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
PDE4D Q08499 1/20 0.33
S1PR1 P21453 1/20 0.33
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
HTR1A P08908 1/20 0.32
ADRB3 P13945 1/20 0.32
TSHR P16473 1/20 0.32
SLC6A4 P31645 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2592497 0.92 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDGAAHDAC4
SCHEMBL2592359 0.91 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDGAAHDAC4
SCHEMBL2592149 0.88 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDGAAHDAC4
SCHEMBL2591764 0.88 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDGAAHDAC4
SCHEMBL14737619 0.86 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDGAAHDAC4
SCHEMBL14734759 0.86 PDE4D (0.35) KDM4EHDAC4HDAC2HDAC8PDE4D
SCHEMBL2592461 0.86 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDGAAHDAC4
SCHEMBL2592008 0.85 KDR (0.34) HDAC4HDAC2HDAC8NPC1RAB9A
SCHEMBL2591750 0.85 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDGAAHDAC4
SCHEMBL2589336 0.85 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDGAAHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A ALDH1A1 824/4885KDM4E 1593/4885HPGD 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.